Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients
详细信息 查看全文
- 作者：Niels Halama1 ; 2 ; 3 ; niels.halama@nct-heidelberg.de" class="auth_mail" title="E-mail the corresponding author ; Inka Zoernig1 ; Anna Berthel1 ; 2 ; Christoph Kahlert4 ; 6 ; Fee Klupp4 ; Meggy Suarez-Carmona1 ; Thomas Suetterlin1 ; 2 ; Karsten Brand5 ; Juergen Krauss1 ; Felix Lasitschka5 ; Tina Lerchl1 ; 2 ; Claudia Luckner-Minden1 ; Alexis Ulrich4 ; Moritz Koch6 ; Juergen Weitz6 ; Martin Schneider4 ; Markus W. Buechler4 ; Laurence Zitvogel7 ; Thomas Herrmann8 ; Axel Benner9 ; Christina Kunz9 ; Stephan Luecke9 ; Christoph Springfeld1 ; Niels Grabe1 ; 2 ; Christine S. Falk10 ; 11 ; Dirk Jaeger1 ; 2 ; 11
- 刊名：Cancer Cell
- 出版年：2016
- 出版时间：11 April 2016
- 年：2016
- 卷：29
- 期：4
- 页码：587-601
- 全文大小：5275 K
文摘
- •
CCL5 is produced by CD4+ and CD8+ T lymphocytes in colorectal cancer liver metastases
- •
CCL5's natural receptor CCR5 is found on tumor cells, lymphocytes and myeloid cells
- •
Inhibition of CCR5 leads to repolarization of tumor-associated macrophages
- •
CCR5 inhibition leads to objective clinical responses in colorectal cancer patients